Dr. Chunrong Tong, Hematologist - Beijing, China

Dr. Chunrong Tong - Hematologist

About Dr. Chunrong Tong

Dr. TONG is the leading expert in immunotherapy and targeted therapy at the Gobroad Medical (Hematology) Research Center and she is the research director and the director of Hematology Department 1 (General Hematology) at Beijing Gobroad Boren Hospital. She has been engaged in the clinical practice and experimental research of hematology for more than 30 years.

Professional Expertise:

Dr. TONG specializes in the integrative diagnosis (integrating clinical history and various laboratory diagnostic techniques) and comprehensive treatment (chemotherapy, immunotherapy, targeted therapy, traditional Chinese medicine, etc.) of various malignant hematological tumors. She emphasizes personalized precision treatment and is particularly adept in immunotherapy for hematologic malignancies.

Research Achievements:

As one of the early experts in China to engage in immunotherapy, Dr. TONG is recognized internationally for his pioneering work in CAR-T cell therapy for refractory and relapsed hematologic malignancies. She led her team in collaboration with enterprises to be the first in China to use the second-generation CD19-41BB-CAR-T cells to treat refractory and relapsed acute B-lymphoblastic leukemia. Subsequently, they developed multiple CAR-T clinical applications targeting a variety of antigens, including CD1a, CD4, CD7, CD20, CD22, CD30, CD33, CD70, CD79b, CD123, CD138, CD371, among others. Boren Hospital is one of the leading centers globally in terms of the number of CAR-T clinical cases and the variety of targets. Dr. TONG has presented numerous research findings at ASH, EHA, EBMT, and JSH conferences, with several papers published in renowned journals such as Leukemia, Blood Cancer Journal and American Journal of Hematology. She also focuses on developing various immunotherapy technologies, including neoantigen immunotherapy, for treating hematologic malignancies and solid tumors.